Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism  by Quarles, L. Darryl et al.
Kidney International, Vol. 34 (1988), pp. 840—844
Oral calcitriol and calcium: Efficient therapy for uremic
hyperparathyroidism
L. DARRYL QUARLES, GIoi A. DAvIDA!, STEVE J. SCHWAB, DOROTHY W. BARTHOLOMAY,
and BRUCE LOBAUGH
Departments of Medicine, Pathology and Surgery, Duke University Medical Center, Durham, North Carolina, USA
Oral calcitriol and calcium: An efficient therapy for uremic hyperpara-
thyroidism. Therapy with orally administered calcitriol often does not
adequately control the biochemical manifestations of secondary hyper-
parathyroidism in uremic patients. This may be due to inadequate
serum concentrations of 1 ,25(OH)2 vitamin D and/or to insufficient
dietary calcium supplementation. In the present study, therefore, we
examined the effect on parathyroid function of calcitriol and calcium
carbonate, administered orally, in doses sufficient to normalize the
serum l,25(OH)2 vitamin D and calcium concentrations. After nine
months of combined therapy, marked suppression of immunoreactive
PTH occurred in the absence of hypercalcemia. Furthermore, pro-
longed therapy resulted in additional suppression of the PTH concen-
trations comparable in magnitude to that reported following intravenous
calcitriol therapy and was associated with a mild degree of hypercalce-
mia similar to that which occurs with intravenous therapy. Euparathy-
roidism was achieved in 25% of the patients by 15 months of treatment.
In conclusion, secondary hyperparathyroidism can be effectively con-
trolled with combined oral therapy without significant hypercalcemia in
selected patients with end-stage renal failure. This salutary effect may
result from direct actions of I ,25(OH),D on the parathyroid gland and!
or gastrointestinal tract, or from an overall action of combined treat-
ment to restore calcium homeostasis.
The optimal therapy for secondary hyperparathyroidism in
patients with end-stage renal disease (ESRD) has not been
established. Therapeutic strategies, using either high-dose oral
calcium carbonate [1, 2] or vitamin D analogues, alone or in
combination with phosphate binders [3—5], have not universally
resulted in adequate suppression of PTH secretion and often
have been associated with significant hypercalcemia [6, 7].
More recently, intravenous calcitriol therapy has been advo-
cated as more effective than conventional oral therapies [8, 91.
The absence of an efficient oral therapy may be due to the
incomplete restoration of all factors necessary for the mainte-
nance of calcium homeostasis; particularly, the provision of
adequate calcium intake and the normalization of serum calci-
triol concentrations. In this regard, calcitriol is necessary for
normal gastrointestinal absorption of calcium and may be
important in suppression of PTH synthesis [10, 11]. Therefore,
we investigated whether secondary hyperparathyroidism in
patients with ESRD could be effectively treated with a combi-
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nation of orally administered calcitriol, in doses sufficient to
normalize the serum calcitriol concentration, and dietary sup-
plementation of calcium, as calcium carbonate, administered in
an amount adequate to normalize the serum calcium concentra-
tion. Our results show that combined therapy with calcitriol and
calcium results in marked suppression of PTH secretion, com-
parable to that reported with intravenous therapy. Euparathy-
roidism was achieved in several subjects. Moreover, the dec-
rement in PTH occurred without the development of significant
hypercalcemia.
Methods
Patients
We selected eight, chronic maintenance hemodialysis pa-
tients who were being treated with four hours of dialysis thrice
weekly at Duke University. Criteria for inclusion were: serum
calcium less than 10 mgldi, serum phosphorus less than 7.0 mg/
dl, and serum immunoreactive PTH greater than 65 pg/mi. Five
patients were female and three were male. The average age of
the patients was 53 5 years (range 30 to 69). No patient had
significant residual renal function. The average duration of
end-stage renal disease as estimated by the onset of hemodial-
ysis was approximately five years. The underlying causes of
renal failure were primary glomerulonephritis in 2, hyperten-
sion in 3, and unknown in 3. No patients had diabetes mellitus
or were receiving steroids.
Treatment protocol
For at least four months prior to beginning this study, all
patients had been receiving variable amounts of calcium car-
bonate between meals and aluminum-containing phosphate
binders with meals to control serum phosphorus concentra-
tions. Prior to the initiation of this study, four patients were
receiving low dose calcitriol (0.25 pg/day) and four were taking
no vitamin D or its analogues. During this period serum
calcium, phosphorus and alkaline phosphatase were measured
at monthly intervals. In addition, at the outset of the study
intact PTH, ionized calcium and calcitriol concentrations were
measured in each patient on the existing therapeutic regimen.
These served as baseline measurements for subsequent com-
parisons. In one patient the baseline intact PTH was estimated
from results obtained from a mid-region assay, The mid region
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assay correlates linearly with the intact assay (r2 = 0.51; P =
0.0001).
The protocol began with the administration of calcitriol
(Rocaltrol, Hoffman La Roche, Nutley, New Jersey, USA) in
increasing doses until the serum calcitriol concentrations ex-
ceeded 15 pg/mi (normal range 15 to 50). Rocaltrol was taken
orally in divided doses twice or thrice daily. Concomitantly,
calcium carbonate was administered with each meal and ad-
justed to titrate the serum calcium to between 10.0 and 10.5 mg/
dl. All between meal supplements of calcium were discontin-
ued. Further adjustments in the dose of Rocaltrol and calcium
carbonate were made to maintain the serum calcium and
calcitriol concentrations within the normal range. Therapy was
temporarily interrupted if calcium levels exceeded 11.5 mg/dl.
The calcium concentration of the dialysate was maintained at
1.75 mmol/liter (3.5 mEq/liter) throughout the study. The
amount of aluminum containing phosphate binders was ad-
justed to maintain the serum phosphorus concentration be-
tween 3.0 and 6.0 mg/dl. Patients were instructed in a diet
consisting of an estimated 900 mg phosphorus and 800 mg
calcium. Thereafter, serum calcium, phosphorus and alkaline
phosphatase determinations were repeated monthly. Reported
values represent the concentration averaged over the entire
period of study. Serum intact PTH and ionized calcium tnea-
surements were repeated at approximately 9 and 15 months
after initiating therapy.
Analytical methods
Parathyroid hormone was measured by radioimmunoassay;
the Allegro PTH assay (Nichols Institute, San Juan Capistrano,
California, USA) is specific for the intact, secreted, biological-
ly-active 84 amino-acid PTH molecule [12]. The concentration
of intact PTH is a more accurate measure of PTH secretion
since biologically inactive circulating fragments of PTH which
accumulate because of impaired renal clearances are not de-
tected by this system. Intra- and interassay coefficients of
variation are 5.7 and 14.9%, respectively. A concentration
below 165 pg/mI is associated with mild bone disease in patients
with renal failure, while 65 pg/mI is the upper limit in apparently
healthy subjects [13]. Total calcium, phosphorus and alkaline
phosphatase were measured by automated methods (Beckman
auto analyzer, Beckman Institution Co, Somerset, New Jersey,
USA). Ionized calcium was determined by an ICAI analyzer
(Radiometer Company, Copenhagen, Denmark). Serum 1,25
dihydroxyvitamin D (calcitriol) concentrations were measured
by the calf thymus receptor assay described by Reinhardt et al
[141, purchased from Instar Corp. (Stillwater, Minnesota,
USA). Established intra- and interassay coefficients of variation
are 5.4 and 16%, respectively.
Statistics
The effect of therapy was analyzed by the Friedman analysis
of variance technique, a non-parametric procedure for repeated
measures data. Differences in response at the three sampling
intervals (0, 9, and 15 months of therapy) were detected using
the Wilcoxin signed ranks test with a Bonferonni correction for
multiple comparisons [15]. Differences in selected biochemis-
tries measured monthly in individual patients were analyzed by
Kendall Tau [16]. Multiple regression was performed using
INT-PTH expressed in ranks as the dependent variable and
Table 1. Mean alterations in the dose of calcitnol, calcium
carbonate, and phosphate binders before, 9 and 15 months after
combined therapy with calcitriol and calcium carbonate
Time
months
Calcitriol
pg/day
Calcium
carbonates
Aluminum
hydroxide
g/day
0 0.13 0.05 1.3 0.6 3.5 0.8
9.0 0.60 0.07 1.9 0.5 3.2 1.0
15.0 0.64 0.06 2.6 0.6 2.2 0.7
Administered exclusively with meals during period of therapy.
ionized calcium, phosphorus, alkaline phosphatase, and calci-
triol concentrations as predictors in order to explore possible
functional relationships among the variables that could account
for any decrement in PTH concentration associated with ther-
apy. All analyses were performed using the Statistical Analysis
System Version 6 software (SAS Institute, Cary, North Caro-
lina, USA).
Results
During the period of treatment, the requisite dose of calcitriol
necessary to establish and maintain a normal serum calcitriol
concentration averaged approximately 0.6 micrograms per day
(Table 1). During the first nine months of the study, the daily
calcitriol dose was distributed as follows: 0.5 micrograms in six
patients; 0.75 micrograms in one; and 1.0 microgram in one.
During the latter period of therapy three patients received 0.5
micrograms per day, four patients received 0.75 micrograms per
day, and one continued to receive 1.0 microgram per day.
Increasing amounts of calcium carbonate were administered
during the study period compared to baseline doses; moreover,
during the period of investigation, calcium was administered
exclusively with meals and titrated to achieve a serum calcium
concentration near the upper limit of normal (Table 1). In
concert with the administration of dietary calcium carbonate,
the dose of aluminum containing antacids was reduced during
the last period of study (Table 1). All aluminum-containing
phosphate binders were discontinued in one patient.
At the outset of the study, the serum calcitriol concentration
was below normal in all patients (Table 2). After intensified
treatment with calcitriol, the serum calcitriol concentration
increased from a baseline concentration of 6.7 to 21.8 pg/mI and
was maintained at this concentration during the study period
(Table 2). The concentration of ionized calcium increased from
a baseline value of 1.10 to 1.20 and 1.27 mmol/liter at 9 and 15
months of therapy, respectively (Table 2). In addition, the total
serum calcium concentration, measured monthly, increased
progressively and significantly (P < 0.05) in each patient
throughout the period of observation (Fig. 1). The average
concentration of this cation, however, was maintained within
the normal range. Transient hypercalcemia developed in sev-
eral patients during the second period of observation and
resolved with temporary cessation of therapy (Fig. 1). The
serum phosphorus concentration was not different from base-
line values in spite of a reduction in the dose of aluminum-
containing antacids (Table 2).
At the outset of therapy, severe hyperparathyroidism, evi-
denced by the grossly-supranormal intact PTH levels, prevailed
(Table 2). Significant reductions in the serum PTH concentra-
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Table 2. Serum biochemistries in chronic maintenance hemodialysis patients before, 9 and 15 months after combined therapy with calcitriol
and calcium carbonate
Months time
Ionized
calcium
mmoi/liter
Phosphorus
mg/dl
Alkaline
phosphatase
U/liter
Calcitriol
pg/mi
Intact parathyroid hormone
pg/mi
%
decrease
0 1.10 0.27 5.5 0.3 295 65 6.7 1.7 968 176 0
9 1.20 0.03a 4,4 0.2 177 30 21.8 2.3a 607 I57- 44 7a
15 1.27 0.04 4.5 0.5 97 20.9 1.4 365 149a,b 71 9'
(Normal range) (1.19—1.31) (2.7—4.6) (20—96) (15—50) (13—64)
Values represent the mean SEM. Data within each column were compared by Wilcoxin's signed ranks test with a Bonferonm correction
for multiple comparisons.a Significant difference from time 0 at P < 0.05l, Significant difference from 9 months at P < 0.05
Time, months
Fig. 1. The monthly serum total calcium concentration in 8 patients
with end-stage renal disease maintained on chronic hemodialysis as a
function of time on combined therapy with calcium and oral calcitriol.
Each symbol represents the serial measurements in individual patients;
all patients demonstrated a significant increase in serum calcium by
Kendall Tau at P < 0.05. The normal range is indicated by the shaded
area.
tions occurred in all patients after nine months of therapy and
further decrements were observed in the majority of subjects
after 15 months (Table 2; Fig. 2). Indeed, after prolonged
therapy, the mean PTH concentrations were reduced by 71%
compared to pretreatment concentrations. Moreover, the con-
centration of intact PTH was normalized in two patients and
reduced into the range associated with low bone remodeling in
three (Fig. 2). Thus, the PTH was effectively normalized in
these patients (64 6.4 pg/ml, normal range 13 to 64). The three
remaining patients had significant reductions in PTH but the
magnitude of the decrement was less. These patients had the
highest pretreatment concentrations of PTH. Consistent with
the decrease in PTH, the mean alkaline phosphatase concen-
tration was significantly reduced by the combined therapeutic
regimen, falling to normal in the majority of patients (Table 2).
Multiple regression analysis revealed that of the biochemical
variables measured, serum ionized calcium and calcitriol con-
centrations significantly and independently accounted for the
decrement in PTH (P = 0.0014 and 0.032, respectively; r2 =
0.56; P < 0.001); inclusion of both variables provided signifi-
Fig. 2. Serum intact PTH concentrations in 8 patients with end-stage
renal disease maintained on hemodialysis as a function of time on
combined therapy with calcium carbonate and oral calcitriol. Symbols
represent serial determinations in individual patients. The upper limit of
normal is delineated by the horizontal shaded area.
cantly greater predictive power than either variable considered
individually.
Discussion
The factors responsible for genesis of secondary hyperpara-
thyroidism in patients with ESRD are well known, yet in the
uremic environment, progressive hyperparathyroidism often
occurs in spite of efforts to normalize serum phosphorus and
calcium concentrations [171. This may result from failure to
fully restore the milieu necessary for the maintenance of
calcium homeostasis. In this regard, most dialysis patients
consume a diet deficient in calcium which, along with the
absence of calcitriol, results in the inadequate gastrointestinal
absorption of calcium [10, 111. In addition, recent studies
illustrate that calcitriol, the most potent vitamin D analogue,
directly inhibits the synthesis of PTH and alters the set point for
secretion of PTH [18—21]. Thus, restoration of the serum
calcitriol concentrations and provision of adequate dietary
calcium should together restore normal gastrointestinal calcium
absorption, and possibly lead to more effective suppression of
synthesis and secretion of parathyroid hormone.
In our investigations we administered doses of calcitriol
sufficient to normalize the serum calcitriol concentration, and
16
14
12
10
8
6
—10
a
0
E
0
-c
>1)
CU
CU
a
C
2000
1000
0
a0)Ca
a
E
0z
0 10 20
0 9 15
Time, months
Quarles et a!: Oral therapy for urernic hyperparathyroidis,n 843
gave calcium carbonate with meals to supplement dietary
calcium and to augment phosphate binding. This therapeutic
approach resulted in an overall reduction in serum PTH con-
centrations of 70% after 15 months, even achieving euparathy-
roidism in several subjects (Table 2; Fig. 2). Moreover, during
the initial nine months of therapy, significant reductions in PTH
concentrations were observed in the absence of hypercalcemia.
During the last period of observation, however, transient mild
hypercalcemia was observed in several patients, but all re-
sponded to reductions in the doses of calcium carbonate and
calcitriol.
The effectiveness of our therapy to suppress PTH may be due
to several factors. The intact assay that we used may be a more
direct measure of PTH secretion, since it does not detect
circulating inactive fragments of PTH. Others may also have
achieved comparable suppression of PTH with oral therapy, but
the use of less effective assays may have obscured this outcome
[6]. Alternatively, the salutary effect of combined therapy may
have resulted from specific actions of calcitriol on the gastro-
intestinal tract to augment the absorption of calcium alone or in
combination with a direct effect on the parathyroid gland to
suppress PTH synthesis and release. Indeed, multiple regres-
sion analysis indicates that the increase in calcitriol concentra-
tion had a significant effect in suppressing PTH concentrations.
While this is consistent with an effect of calcitriol at the level of
the parathyroid gland (vide supra), an alternative explanation
might be that this therapy provides a more effective and
continuous augmentation of the intestinal absorption of cal-
cium. Whether this therapy allows for a more sustained physi-
ologic calcium homeostasis over a 24 hour period requires
further study. Marked fluctuations in serum calcium concentra-
tion, however, typically occur during hemodialysis and the
interdialytic period in patients who do not receive vitamin D
[22]. The contribution of these fluctuations in the serum calcium
to the maintenance of hyperparathyroidism should be consid-
ered. A related issue is whether combined oral therapy would
allow for the maintenance of the serum calcium concentration
using a lower dialysate calcium and thereby prevent the ten-
dency to develop hypercalcemia observed with more prolonged
use of calcitriol.
Serum phosphorus concentration was effectively controlled
with combined oral therapy. This may in part be due to the
chelation of dietary phosphorus by calcium carbonate. The
amount of calcium carbonate administered was appreciably less
than that reported effective in controlling serum phosphorus
concentrations [1]. The suppression of PTH and the consequent
reduction in bone turnover may also have contributed to the
decline in serum phosphorus analogous to that observed follow-
ing parathyroidectomy. Continuation of phosphate binders was
necessary to control the serum phosphorus concentration in the
majority of patients.
Although the majority of patients showed dramatic reduc-
tions in PTH, the degree of suppression was less in the three
patients with the highest baseline concentrations of PTH.
Additional time may be necessary to achieve control of hyper-
parathyroidism in these patients. Alternatively, these patients
may represent a subset with more severe parathyroid hyperpla-
sia who continue to have elevated PTH release because of
increased gland mass, in spite of maximal suppression of PTH
secretion. Observations which demonstrate a correlation be-
tween PTH secretion and gland mass support this possibility
[23]. The normalization of PTH concentrations in several pa-
tients without hypercalcemia, as demonstrated in our study,
however, is consistent with regression of the parathyroid gland
hyperplasia in some of the patients.
Our results differ from studies which have demonstrated the
ineffectiveness of oral calcitriol. This may be due to differences
in patient selection or intensity of treatment. Studies showing
little effect of oral calcitriol may be confounded by the failure to
document that: 1) sufficient doses of this hormone were admin-
istered; 2) adequate dietary calcium was provided; or 3) patients
with similar degrees of hyperplasia were selected [7, 8]. PTH
suppression by oral therapy has been reported in other inves-
tigations in association with substantial degrees of hypercalce-
mia [6, 7]. In our study, the calcemic response was less for the
degree of PTH suppression and similar to that observed with
intravenous therapy (vida infra) [81. This may result from the
co-administration of aluminum containing phosphate binders
and calcium with meals. In this regard, aluminum has recently
been shown to interfere with calcium absorption in a setting of
vitamin D repletion [241. Nevertheless, as demonstrated by this
study, hypercalcemia is not a universal occurrence following
oral calcitriol therapy. Nonetheless, reductions in the dialysate
calcium concentration andlor oral calcium supplementation
may be needed with any form of vitamin D therapy in order to
minimize the tendency to hypercalcemia following prolonged
therapy.
Our observations highlight the need to resolve the role of oral
versus intravenous calcitriol administration in the management
of hyperparathyroidism in patients with ESRD. The intrave-
nous administration of calcitriol has recently been advocated
because oral therapies have been reported ineffective in achiev-
ing adequate serum calcitriol concentrations and suppressing
PTH secretion without the concurrence of significant hypercal-
cemia [8, 9], a contention not supported by our observations.
Central to this issue is whether the pharmacologic concentra-
tion achieved with intravenous therapy offers any advantage in
PTH suppression. To date an additional benefit of such ex-
tremely high concentrations has not been unequivocally estab-
lished. On the other hand, in vitro studies show maximum
inhibition of PTH mRNA synthesis at physiologic concentra-
tions of 1,25 dihydroxyvitamin D [20, 21]. Moreover, the degree
of PTH suppression with low physiologic concentration of
calcitriol as demonstrated in our study is equivalent to that
observed following the parenteral administration of calcitriol [8,
9]. In addition, the potential untoward effects of the supraphys-
iologic concentrations attendant upon intravenous therapy have
not been fully explored. Indeed, high concentrations of calci-
trio! do increase bone resorption in vitro [25].
In conclusion, recent experimental evidence supports a vital
role for calcitriol in the normal feedback suppression of both
PTH synthesis and secretion, in addition to its established
effects on the gastrointestinal absorption of calcium. While our
results are preliminary and involve relatively small numbers of
patients, our studies suggest that attaining low normal circulat-
ing concentrations of this vitamin D metabolite, along with
dietary calcium supplementation in the form of calcium carbon-
ate, is sufficient to adequately control the biochemical manifes-
tations of hyperparathyroidism in selected patients with ESRD.
A prospective controlled trial, which compares the relative
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effectiveness of oral versus intravenous calcitriol, should be
performed in patients with comparable degrees of parathyroid
hyperplasia with similar dietary calcium intake and dialysate
calcium concentrations and with attention to the serum concen-
tration of 1 ,25(OH)2D achieved in order to determine the
optimal route of calcitriol administration.
Reprint requests to L. Darryl Quarles, M.D., Division of Nephro/-
ogy, Box 3285, Duke University Medical Center, Durham, North
Carolina 27710, USA.
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